CULLINAN THERAPEUTICS, INC. Earnings Per Share (Basic)
CULLINAN THERAPEUTICS, INC. (CGEM) reported Earnings Per Share (Basic) of -$0.69 per share for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2024-11-07
- CULLINAN THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2024-09-30 was -$0.69.
- CULLINAN THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2024-06-30 was -$0.75.
- CULLINAN THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2024-03-31 was -$0.86.
- CULLINAN THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2023-12-31 was -$0.60.
- CULLINAN THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$3.69, a 250.00% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was $2.46.
- CULLINAN THERAPEUTICS, INC. earnings per share, basic for fiscal 2021 was -$1.52.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$0.69 10-Q · filed 2024-11-07 | -$1.46 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$2.30 10-Q · filed 2024-11-07 | -$2.92 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2024-06-30 | -$0.75 10-Q · filed 2024-08-08 | -$1.61 10-Q · filed 2024-08-08 | -$2.23 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$3.14 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2024-03-31 | -$0.86 10-Q · filed 2024-05-15 | -$1.47 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.38 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$3.19 derived: net income ÷ weighted average shares · filed 2026-04-28 |
| 2023-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$2.32 derived: net income ÷ weighted average shares · filed 2026-04-28 | -$3.69 10-K · filed 2024-03-14 |
| 2023-09-30 | -$0.91 10-Q · filed 2024-11-07 | -$1.73 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$3.15 10-Q · filed 2024-11-07 | -$3.69 derived: net income ÷ weighted average shares · filed 2024-11-07 |
| 2023-06-30 | -$0.82 10-Q · filed 2024-08-08 | -$2.24 10-Q · filed 2024-08-08 | -$2.78 derived: net income ÷ weighted average shares · filed 2024-08-08 | -$3.30 derived: net income ÷ weighted average shares · filed 2024-08-08 |
| 2023-03-31 | -$1.42 10-Q · filed 2024-05-15 | -$1.96 derived: net income ÷ weighted average shares · filed 2024-05-15 | -$2.49 derived: net income ÷ weighted average shares · filed 2024-05-15 | $1.48 derived: net income ÷ weighted average shares · filed 2024-05-15 |
| 2022-12-31 | -$0.59 derived: net income ÷ weighted average shares · filed 2024-03-14 | -$1.13 derived: net income ÷ weighted average shares · filed 2024-03-14 | $2.72 derived: net income ÷ weighted average shares · filed 2024-03-14 | $2.46 10-K · filed 2024-03-14 |
| 2022-09-30 | -$0.54 10-Q · filed 2023-11-08 | $3.32 derived: net income ÷ weighted average shares · filed 2023-11-08 | $3.07 10-Q · filed 2023-11-08 | $2.38 derived: net income ÷ weighted average shares · filed 2023-11-08 |
| 2022-06-30 | $3.90 10-Q · filed 2023-08-10 | $3.65 10-Q · filed 2023-08-10 | $2.96 derived: net income ÷ weighted average shares · filed 2023-08-10 | $2.58 derived: net income ÷ weighted average shares · filed 2023-08-10 |
| 2022-03-31 | -$0.27 10-Q · filed 2023-05-11 | -$1.03 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$1.43 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$1.79 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | -$0.76 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.16 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.52 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.52 10-K · filed 2023-03-09 |
| 2021-09-30 | -$0.40 10-Q · filed 2022-11-14 | -$0.76 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.76 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$0.36 10-Q · filed 2022-08-10 | -$0.37 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |